Walleye Trading
ALXN

Walleye Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,900
Closed -$6.96M – 6112
2021
Q2 		$6.96M Buy
37,900
+19,400
+105% +$3.33M 0.03% 624
2021
Q1 		$2.83M Sell
18,500
-50,200
-73% -$7.77M 0.01% 1065
2020
Q4 		$10.7M Sell
68,700
-14,900
-18% -$1.91M 0.05% 365
2020
Q3 		$9.57M Sell
83,600
-37,100
-31% -$4M 0.05% 306
2020
Q2 		$13.5M Sell
120,700
-15,800
-12% -$1.68M 0.09% 192
2020
Q1 		$12.3M Sell
136,500
-59,600
-30% -$5.85M 0.09% 137
2019
Q4 		$21.2M Buy
196,100
+102,800
+110% +$11M 0.15% 115
2019
Q3 		$9.14M Buy
93,300
+73,300
+367% +$8.26M 0.08% 227
2019
Q2 		$2.62M Sell
20,000
-39,800
-67% -$5.13M 0.02% 849
2019
Q1 		$8.08M Sell
59,800
-5,300
-8% -$659K 0.06% 310
2018
Q4 		$6.34M Buy
65,100
+54,600
+520% +$6.45M 0.05% 369
2018
Q3 		$1.46M Sell
10,500
-33,600
-76% -$4.21M 0.01% 1672
2018
Q2 		$5.47M Sell
44,100
-24,200
-35% -$2.83M 0.03% 552
2018
Q1 		$7.61M Buy
68,300
+19,300
+39% +$2.31M 0.04% 349
2017
Q4 		$5.86M Buy
49,000
+17,200
+54% +$2.09M 0.03% 581
2017
Q3 		$4.46M Buy
31,800
+4,900
+18% +$666K 0.02% 730
2017
Q2 		$3.27M Buy
26,900
+3,600
+15% +$419K 0.02% 846
2017
Q1 		$2.82M Buy
23,300
+22,000
+1,692% +$2.84M 0.02% 839
2016
Q4 		$159K Sell
1,300
-7,200
-85% -$881K ﹤0.01% 2946
2016
Q3 		$1.04M Buy
8,500
+5,000
+143% +$644K 0.01% 1508
2016
Q2 		$408K Sell
3,500
-10,600
-75% -$1.5M ﹤0.01% 2390
2016
Q1 		$1.96M Sell
14,100
-10,600
-43% -$1.56M 0.02% 868
2015
Q4 		$4.71M Buy
24,700
+2,600
+12% +$454K 0.05% 386
2015
Q3 		$3.46M Sell
22,100
-155,200
-88% -$28.3M 0.03% 429
2015
Q2 		$32M Buy
177,300
+169,400
+2,144% +$29.2M 0.32% 35
2015
Q1 		$1.37M Buy
7,900
+7,600
+2,533% +$1.38M 0.01% 827
2014
Q4 		$56K Sell
300
-300
-50% -$55.6K ﹤0.01% 3184
2014
Q3 		$99K Sell
600
-300
-33% -$49.3K ﹤0.01% 2661
2014
Q2 		$141K Buy
+900
New +$142K ﹤0.01% 2230

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Walleye Trading's ALXN Position: Q3 2021 in Review

Walleye Trading sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,742 shares — an estimated $3.44M sold.

Walleye Trading first reported a position in ALXN in Q3 2013 and held it in 24 quarters. The position peaked at $5.37M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Walleye Trading reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Walleye Trading sold 18,742 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.44M.
  • Walleye Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 24 quarters.
  • Walleye Trading's Alexion Pharmaceuticals position peaked at $5.37M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.